Jason Masters appointed Independent Non-Executive Director of Celtaxsys Aus Pty Ltd

We are pleased to announce that Jason Masters has been appointed an Independent Non-Executive Director of Celtaxsys Aus Pty Ltd is a subsidiary of Celtaxsys of the USA which is a privately-held clinical stage drug development company with operations in San Francisco, CA and Atlanta, GA.

Celtaxsys is leveraging deep knowledge of innate immune biology and pathology to build a portfolio of novel immune modulating drugs. Via both acquisition and internal research, Celtaxsys is designing a diversified pipeline to provide first-in-class or best-in-class therapeutics for important diseases such as Cystic Fibrosis (CF), Systemic Sclerosis (SSc) and Idiopathic Pulmonary Fibrosis (IPF). Celtaxsys’ flagship program, CTX-4430, is a first-in-class oral LTA4 Hydrolase inhibitor for treatment of CF lung inflammation and entering Phase clinical 2 trials in 2013.

Print Friendly, PDF & Email

Leave a Reply

Your email address will not be published. Required fields are marked *